Published in Blood on October 01, 2010
Sustained effector function of IL-12/15/18-preactivated NK cells against established tumors. J Exp Med (2012) 1.86
Effect of donor KIR2DL1 allelic polymorphism on the outcome of pediatric allogeneic hematopoietic stem-cell transplantation. J Clin Oncol (2013) 1.59
γδ T-cell reconstitution after HLA-haploidentical hematopoietic transplantation depleted of TCR-αβ+/CD19+ lymphocytes. Blood (2015) 1.56
Immunogenicity of pluripotent stem cells and their derivatives. Circ Res (2013) 1.19
Natural killer cell engineering for cellular therapy of cancer. Tissue Antigens (2011) 1.18
Cellular and molecular basis of haploidentical hematopoietic stem cell transplantation in the successful treatment of high-risk leukemias: role of alloreactive NK cells. Front Immunol (2013) 1.10
Role of common-gamma chain cytokines in NK cell development and function: perspectives for immunotherapy. J Biomed Biotechnol (2011) 1.09
KIR B haplotype donors confer a reduced risk for relapse after haploidentical transplantation in children with ALL. Blood (2014) 1.06
TLR/NCR/KIR: Which One to Use and When? Front Immunol (2014) 1.03
Autologous stem cell transplant recipients tolerate haploidentical related-donor natural killer cell-enriched infusions. Transfusion (2012) 0.94
Natural killer cell-based therapies. F1000 Med Rep (2011) 0.93
Low immunogenicity of neural progenitor cells differentiated from induced pluripotent stem cells derived from less immunogenic somatic cells. PLoS One (2013) 0.91
Recognition of adult and pediatric acute lymphoblastic leukemia blasts by natural killer cells. Haematologica (2014) 0.91
The role of KIR genes and ligands in leukemia surveillance. Front Immunol (2013) 0.91
Impact of HCMV Infection on NK Cell Development and Function after HSCT. Front Immunol (2013) 0.90
Identification of human NK17/NK1 cells. PLoS One (2011) 0.86
Natural killer cell differentiation from hematopoietic stem cells: a comparative analysis of heparin- and stromal cell-supported methods. Biol Blood Marrow Transplant (2011) 0.85
Killer immunoglobulin-like receptor (KIR) and HLA genotypes affect the outcome of allogeneic kidney transplantation. PLoS One (2012) 0.84
Melanoma immunoediting by NK cells. Oncoimmunology (2012) 0.84
Concise review: immunologic lessons from solid organ transplantation for stem cell-based therapies. Stem Cells Transl Med (2013) 0.83
Effects of KIR ligand incompatibility on clinical outcomes of umbilical cord blood transplantation without ATG for acute leukemia in complete remission. Blood Cancer J (2013) 0.83
Molecular monitoring of minimal residual disease in two patients with MLL-rearranged acute myeloid leukemia and haploidentical transplantation after relapse. Exp Hematol Oncol (2012) 0.81
Role of natural killer cell subsets and natural cytotoxicity receptors for the outcome of immunotherapy in acute myeloid leukemia. Oncoimmunology (2015) 0.79
Optimal selection of natural killer cells to kill myeloma: the role of HLA-E and NKG2A. Cancer Immunol Immunother (2015) 0.79
Uptake of CCR7 by KIR2DS4⁺ NK cells is induced upon recognition of certain HLA-C alleles. J Immunol Res (2015) 0.79
Translational Implications for Off-the-shelf Immune Cells Expressing Chimeric Antigen Receptors. Mol Ther (2016) 0.79
NK Cells and Other Innate Lymphoid Cells in Hematopoietic Stem Cell Transplantation. Front Immunol (2016) 0.78
How do we choose the best donor for T-cell-replete, HLA-haploidentical transplantation? J Hematol Oncol (2016) 0.78
NK cells from malignant pleural effusions are potent antitumor effectors: A clue for adoptive immunotherapy? Oncoimmunology (2013) 0.78
Cytotoxicity and infiltration of human NK cells in in vivo-like tumor spheroids. BMC Cancer (2015) 0.78
Advances in haploidentical stem cell transplantation. Rev Bras Hematol Hemoter (2011) 0.77
The role of NK cells in HIV-1 protection: autologous, allogeneic or both? AIDS Res Ther (2016) 0.77
Cord Blood Mononuclear Cells Have a Potential to Produce NK Cells Using IL2Rg Cytokines. Adv Pharm Bull (2016) 0.77
IL-1β-releasing human acute myeloid leukemia blasts modulate natural killer cell differentiation from CD34+ precursors. Haematologica (2014) 0.76
Interaction of natural killer cells with neutrophils exerts a significant antitumor immunity in hematopoietic stem cell transplantation recipients. Cancer Med (2015) 0.76
Use of Alefacept for Preconditioning in Multiply Transfused Pediatric Patients with Nonmalignant Diseases. Biol Blood Marrow Transplant (2015) 0.76
Inhibition of MMP activity can restore NKG2D ligand expression in gastric cancer, leading to improved NK cell susceptibility. J Gastroenterol (2016) 0.76
Signaling in Effector Lymphocytes: Insights toward Safer Immunotherapy. Front Immunol (2016) 0.76
Engineering Natural Killer Cells for Cancer Immunotherapy. Mol Ther (2017) 0.76
Human Leukocyte Antigen Diversity: A Southern African Perspective. J Immunol Res (2015) 0.75
Graft-versus-Leukemia Effect Following Hematopoietic Stem Cell Transplantation for Leukemia. Front Immunol (2017) 0.75
Human NK Cell Subsets Redistribution in Pathological Conditions: A Role for CCR7 Receptor. Front Immunol (2016) 0.75
qKAT: a high-throughput qPCR method for KIR gene copy number and haplotype determination. Genome Med (2016) 0.75
KIR and their HLA Class I ligands: Two more pieces towards completing the puzzle of chronic rejection and graft loss in kidney transplantation. PLoS One (2017) 0.75
Effect of entinostat on NK cell-mediated cytotoxicity against osteosarcoma cells and osteosarcoma lung metastasis. Oncoimmunology (2017) 0.75
Role of αβ T Cell Depletion in Prevention of Graft versus Host Disease. Biomedicines (2017) 0.75
Peptide-specific engagement of the activating NK cell receptor KIR2DS1. Sci Rep (2017) 0.75
Natural Killer Cells: Angels and Devils for Immunotherapy. Int J Mol Sci (2017) 0.75
Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study. Lancet (2008) 12.59
Innate or adaptive immunity? The example of natural killer cells. Science (2011) 8.68
Survival advantage with KIR ligand incompatibility in hematopoietic stem cell transplantation from unrelated donors. Blood (2003) 3.88
Autologous bone marrow-derived mesenchymal stromal cells in the treatment of fistulising Crohn's disease. Gut (2011) 3.81
Identification, activation, and selective in vivo ablation of mouse NK cells via NKp46. Proc Natl Acad Sci U S A (2007) 3.60
Identification of PVR (CD155) and Nectin-2 (CD112) as cell surface ligands for the human DNAM-1 (CD226) activating molecule. J Exp Med (2003) 3.52
Mesenchymal stem cells inhibit natural killer-cell proliferation, cytotoxicity, and cytokine production: role of indoleamine 2,3-dioxygenase and prostaglandin E2. Blood (2007) 3.38
Human bone marrow derived mesenchymal stem cells do not undergo transformation after long-term in vitro culture and do not exhibit telomere maintenance mechanisms. Cancer Res (2007) 3.19
The B7 family member B7-H6 is a tumor cell ligand for the activating natural killer cell receptor NKp30 in humans. J Exp Med (2009) 3.17
Interaction of human mesenchymal stem cells with cells involved in alloantigen-specific immune response favors the differentiation of CD4+ T-cell subsets expressing a regulatory/suppressive phenotype. Haematologica (2005) 3.11
Unravelling natural killer cell function: triggering and inhibitory human NK receptors. EMBO J (2003) 3.06
Alternatively spliced NKp30 isoforms affect the prognosis of gastrointestinal stromal tumors. Nat Med (2011) 3.03
CD56brightCD16- killer Ig-like receptor- NK cells display longer telomeres and acquire features of CD56dim NK cells upon activation. J Immunol (2007) 2.97
Factors associated with outcomes of unrelated cord blood transplant: guidelines for donor choice. Exp Hematol (2004) 2.81
Characterization of CD56-/CD16+ natural killer (NK) cells: a highly dysfunctional NK subset expanded in HIV-infected viremic individuals. Proc Natl Acad Sci U S A (2005) 2.80
Preclinical characterization of 1-7F9, a novel human anti-KIR receptor therapeutic antibody that augments natural killer-mediated killing of tumor cells. Blood (2009) 2.75
Transforming growth factor beta 1 inhibits expression of NKp30 and NKG2D receptors: consequences for the NK-mediated killing of dendritic cells. Proc Natl Acad Sci U S A (2003) 2.71
The abundant NK cells in human secondary lymphoid tissues require activation to express killer cell Ig-like receptors and become cytolytic. J Immunol (2004) 2.64
Recognition of peptide-MHC class I complexes by activating killer immunoglobulin-like receptors. Proc Natl Acad Sci U S A (2005) 2.55
Melanoma cells inhibit natural killer cell function by modulating the expression of activating receptors and cytolytic activity. Cancer Res (2012) 2.54
Natural killer cells in HIV-1 infection: dichotomous effects of viremia on inhibitory and activating receptors and their functional correlates. Proc Natl Acad Sci U S A (2003) 2.51
Imatinib for refractory chronic graft-versus-host disease with fibrotic features. Blood (2009) 2.51
Human breast cancer cells enhance self tolerance by promoting evasion from NK cell antitumor immunity. J Clin Invest (2011) 2.44
Clinical features, long-term follow-up and outcome of a large cohort of patients with Chronic Granulomatous Disease: an Italian multicenter study. Clin Immunol (2007) 2.38
The graft-versus-leukemia effect using matched unrelated donors is not superior to HLA-identical siblings for hematopoietic stem cell transplantation. Blood (2008) 2.35
Survival after T cell-depleted haploidentical stem cell transplantation is improved using the mother as donor. Blood (2008) 2.34
NK-dependent DC maturation is mediated by TNFalpha and IFNgamma released upon engagement of the NKp30 triggering receptor. Blood (2005) 2.31
The impaired NK cell cytolytic function in viremic HIV-1 infection is associated with a reduced surface expression of natural cytotoxicity receptors (NKp46, NKp30 and NKp44). Eur J Immunol (2003) 2.29
Congenital amegakaryocytic thrombocytopenia: clinical and biological consequences of five novel mutations. Haematologica (2007) 2.23
CpG and double-stranded RNA trigger human NK cells by Toll-like receptors: induction of cytokine release and cytotoxicity against tumors and dendritic cells. Proc Natl Acad Sci U S A (2004) 2.23
Defective expression and function of natural killer cell-triggering receptors in patients with acute myeloid leukemia. Blood (2002) 2.21
Atypical features of familial hemophagocytic lymphohistiocytosis. Blood (2004) 2.21
Late MRD response determines relapse risk overall and in subsets of childhood T-cell ALL: results of the AIEOP-BFM-ALL 2000 study. Blood (2011) 2.18
Mutations in CBL occur frequently in juvenile myelomonocytic leukemia. Blood (2009) 2.15
Impact of allele-level HLA matching on outcomes after myeloablative single unit umbilical cord blood transplantation for hematologic malignancy. Blood (2013) 2.12
What is a natural killer cell? Nat Immunol (2002) 2.11
Cell therapy of stage IV nasopharyngeal carcinoma with autologous Epstein-Barr virus-targeted cytotoxic T lymphocytes. J Clin Oncol (2005) 2.10
NCRs and DNAM-1 mediate NK cell recognition and lysis of human and mouse melanoma cell lines in vitro and in vivo. J Clin Invest (2009) 2.08
The role of chemerin in the colocalization of NK and dendritic cell subsets into inflamed tissues. Blood (2007) 1.99
DNAM-1 and PVR regulate monocyte migration through endothelial junctions. J Exp Med (2004) 1.96
HLA class I, NKG2D, and natural cytotoxicity receptors regulate multiple myeloma cell recognition by natural killer cells. Blood (2004) 1.95
Identification of 4Ig-B7-H3 as a neuroblastoma-associated molecule that exerts a protective role from an NK cell-mediated lysis. Proc Natl Acad Sci U S A (2004) 1.95
A prospective evaluation of degranulation assays in the rapid diagnosis of familial hemophagocytic syndromes. Blood (2012) 1.92
Surface NK receptors and their ligands on tumor cells. Semin Immunol (2006) 1.92
Evidence- and consensus-based practice guidelines for the therapy of primary myelodysplastic syndromes. A statement from the Italian Society of Hematology. Haematologica (2002) 1.91
Natural killer cell-mediated killing of freshly isolated neuroblastoma cells: critical role of DNAX accessory molecule-1-poliovirus receptor interaction. Cancer Res (2004) 1.87
Increased natural cytotoxicity receptor expression and relevant IL-10 production in NK cells from chronically infected viremic HCV patients. Eur J Immunol (2007) 1.86
Cellular ligands of activating NK receptors. Trends Immunol (2005) 1.84
Killer immunoglobulin-like receptors. Curr Opin Immunol (2004) 1.83
The three-dimensional structure of the human NK cell receptor NKp44, a triggering partner in natural cytotoxicity. Structure (2003) 1.82
Phenotypic and functional heterogeneity of human NK cells developing after umbilical cord blood transplantation: a role for human cytomegalovirus? Blood (2011) 1.78
NKp46 and NKG2D recognition of infected dendritic cells is necessary for NK cell activation in the human response to influenza infection. J Immunol (2007) 1.78
Donor/recipient mixed chimerism does not predict graft failure in children with beta-thalassemia given an allogeneic cord blood transplant from an HLA-identical sibling. Haematologica (2008) 1.78
Mesenchymal stromal cells. Ann N Y Acad Sci (2009) 1.76
Impaired Epstein-Barr virus-specific CD8+ T-cell function in X-linked lymphoproliferative disease is restricted to SLAM family-positive B-cell targets. Blood (2010) 1.75
Inherited perforin and Fas mutations in a patient with autoimmune lymphoproliferative syndrome and lymphoma. N Engl J Med (2004) 1.72
Characterization of the defective interaction between a subset of natural killer cells and dendritic cells in HIV-1 infection. J Exp Med (2006) 1.72
Effector and regulatory events during natural killer-dendritic cell interactions. Immunol Rev (2006) 1.71
Fludarabine, cyclophosphamide, antithymocyte globulin, with or without low dose total body irradiation, for alternative donor transplants, in acquired severe aplastic anemia: a retrospective study from the EBMT-SAA Working Party. Haematologica (2010) 1.68
A novel KIR-associated function: evidence that CpG DNA uptake and shuttling to early endosomes is mediated by KIR3DL2. Blood (2010) 1.67
Functional specialization of human circulating CD16 and CD1c myeloid dendritic-cell subsets. Blood (2007) 1.67
Reciprocal regulation of human natural killer cells and macrophages associated with distinct immune synapses. Blood (2007) 1.66
Natural killer cells infiltrating human nonsmall-cell lung cancer are enriched in CD56 bright CD16(-) cells and display an impaired capability to kill tumor cells. Cancer (2008) 1.66
Haematopoietic stem cell transplantation in haemophagocytic lymphohistiocytosis. Br J Haematol (2005) 1.64
The interaction between NK cells and dendritic cells in bacterial infections results in rapid induction of NK cell activation and in the lysis of uninfected dendritic cells. Eur J Immunol (2003) 1.60
Rituximab for the treatment of refractory autoimmune hemolytic anemia in children. Blood (2003) 1.58
Human mesenchymal stem cells and cyclosporin a exert a synergistic suppressive effect on in vitro activation of alloantigen-specific cytotoxic lymphocytes. Biol Blood Marrow Transplant (2005) 1.58
Long-term results of a randomized trial on extended use of high dose L-asparaginase for standard risk childhood acute lymphoblastic leukemia. J Clin Oncol (2005) 1.58
Expression of the DNAM-1 ligands, Nectin-2 (CD112) and poliovirus receptor (CD155), on dendritic cells: relevance for natural killer-dendritic cell interaction. Blood (2005) 1.57
Dual-functional capability of CD3+CD56+ CIK cells, a T-cell subset that acquires NK function and retains TCR-mediated specific cytotoxicity. Blood (2011) 1.56
Downregulation and/or release of NKG2D ligands as immune evasion strategy of human neuroblastoma. Neoplasia (2004) 1.56